Clinical Outcome after Elective Cardiac Surgery in Patients with Liver Cirrhosis

Thesis

Submitted in partial fulfillment for MD degree in Cardiothoracic Surgery

By Ahmad Azmy Algebaly M.B.B.ch,M.Sc

Supervised by

Prof.Dr. Ahmed Abd-Elrahman Hassouna

Professor of Cardiothoracic Surgery Ain Shams University

Prof.Dr. Mohsen Mohammed Abd-Elkareem

Professor of Cardiothoracic Surgery Ain Shams University

Prof.Dr. Hesham Abd-Elrahman Zaki

Professor of Cardiothoracic Surgery Ain Shams University

Doctor. Hatem Yazeed El-Bawab

Ass. Professor of Cardiothoracic Surgery Ain Shams University

Ain Shams University 2008

DEDICATION TO MY Family Who always blessed my life,

Acknowledgments

To *Prof. Dr Ahmed Abd-Elrahman Hassouna:* I deeply appreciate your endorsement. Thanks for your thoughtfulness and your trust until this work come to light. I hope you are satisfied with this good corporation.

To *Prof. Dr. Mohsen Mohamed Abd-ElKareem*: I will always remember your willingness to help me. I wanted personally to let you know how gratifying it to receive your kind support and help. Please accept my sincere thanks. I will always remember your encouragement.

To *Prof. Dr. Hesham Abd-Elrahman Zaki*: All great wards cannot explain my great thanks for him for his great guidance to release this manuscript to light you have a way of explaining things that is easy for me to understand. Not everyone has such a gift. Please accept my sincere gratitude.

No word can fulfill the feeling of gratitude and respect I carry for *Prof. Dr .Hatem Yazeed Elbawab*, for his direction, and fatherly advice through this work.

Lastly I would like to express my deep thanks to Dr. Eman Aboshady, Dr Akram Eldesoky, Misses Shadyah and my colleagues in National Heart Institute and to my family for their help and support. Great thanks for every one helped me to finish this work.

List of Contents

Chapter	Title	Page
1.	Introduction.	1
2.	Aim of the Work.	2
3.	Review of Literature.	3
	o Anatomical Consideration	3
	• Gross and surface Anatomy of the liver.	3
	• Microscopic Anatomy of the liver.	9
	o Physiological consideration of the liver.	13
	 Regulation of the liver blood flow. 	13
	 Hepatobiliary function. 	16
	• Assessment of liver function.	23
	 Pathological Consideration of the Liver. 	30
	• Liver Cirrhosis.	30
	 Pathophysiology of Cirrhosis. 	32
	 Sequalae of liver Cirrhosis. 	34
	o Comorbidity in Cardiac Surgery.	50
	 Cardiac Surgery and the Liver. 	54
	 Effect of Cardiac Surgery on the liver. 	54
	 Effect of liver Cirrhosis on Cardiac Surgery. 	60
4.	Patients and Methods.	73
5 .	Results.	81
6.	Discussion.	143
7.	Conclusion and recommendation.	161
8.	Summary.	161
9.	References.	165
10.	Arabic Summary.	179

List of Abbreviations

ACT	Activated clotting time
AFP	α -Fetoprotein
ALT	Alanine Transaminase
ANOVA	Analysis of variance
AST	Aspartate Transaminase
ATP	Adenosine Tri Phosphate
AVR	Aortic Valve Replacement
Ca_morb	Cardiac morbidity
CABG	Conventional Coronary Artery Bypass Grafting.
CABG_V	Coronary + valve replacement
CBC	Complete Blood Count
CCK	Cholecystokinin
CHP-Cls	Child-Pugh class
CHP-Sc	Child-Pugh Score
СО	Cardiac Output
CHD	Congenital heart disease
CPB	Cardiopulmonary Bypass.
CT scan	Computed tomography
CTP	Child-Turcotte-Pugh system
DVR	Double Valve Replacement
EF	Ejection fraction
ERCP	Endoscopic Retrograde Cholangiopancreatography.
ESRD	End stage renal disease
EuroSCORE	European System for Cardiac Operative Risk Evaluation.
FHF	Fulminant hepatic failure.
GI	Gastrointestinal
НВ	Hemoglobin
HBV	Hepatitis B virus
HCV	Hepatitis C virus
Hep_imp	Hepatic impairment
HPS	Hepatopulmonary syndrome
HTN	Systemic hypertension
HVPG	Hepatic venous pressure gradient
ICG	Indo-Cyanine Green clearance test

IHD	Ischemic Heart Disease
INR	International Normalized Ratio
IV	Intra Venous
LV	Left Ventricle
LVEDD	Left Ventricular End Diastolic Dimension
LVEF	Left Ventricular Ejection Fraction
LVESD	Left Ventricular End Systolic Dimension
LVFS	Left Ventricular Fraction Shortening
MAC	Minimal alveolar concentration
MELD	Mayo End-Stage Liver Disease
Morbid	Morbidity
Mort	Mortality
MR	Mitral regurgitation
MRI	Magnetic Resonance Imaging
MI	Myocardial infarction
MSOF	Multi system organ failure
MVR	Mitral Valve Replacement
MVr	Mitral Valve repair
NAD	Nicotine Amide Dinuclutitde
NHI	National Heart Institute
NPV	Negative Predictive value
NSAIDs	Nonsteroidal anti-inflammatory drugs
NYHA	New York Heart Association
OPCAB	Off pump Coronary Artery Bypass Grafting.
P.A.P.R	Pulmonary artery pressure
P02	Pressure of oxygen
PDR	Percentage disappearance rate
Per. ef	Pericardial effusion
PH	Power of hydrogen ion
Pl. ef	Pleural effusion
PLS	plasma
PLT	Platelets
Postop	Postoperative
PPV	Positive Predictive value
Preop	Preoperative

PT	Prothrombin Time
PTT	Activated Partial Thromboplastin Time
QT	QT Interval
Resp. comp	Respiratory complication
RHD	Rheumatic Heart Disease
ROC curve	Receiver Operating Characteristic curve analysis
RVD	Right ventricle diameter
SD	Standard Deviation
Sens	Sensitivity
SLD	Schistosomal liver disease
SLE	Systemic lupus erythematosis
Spec	Specificity
SPSS	Statistical Package for Social Science
TEE	Transoesophageal Echocardiography
TFPI	Tissue factor pathway inhibitor
TGF-beta1	Transforming growth factor beta1
TNF-alpha	Tumor necrosis factor-alpha
tPA	tissue Plasminogen Activator
Tr	Tricuspid Valve repair
TTE	Transthoracic Echocardiography
uPA	Urokinase Plasminogen activator
US	Ultrasound
Vent. time	Ventilation time
VLDL	Very Low Density Lipoprotein
VWF	Von Willebrand factor
WBCs	White Blood Cells
X. C	Cross clamp
PBC	Primary biliary cirrhosis
PSC	Primary sclerosing cholangitis

LIST OF TABLES

Table No	Subject	Page
1)	Haemodynamic changes in patients with cirrhosis at rest	41
2)	Hemostatic changes In patients with Iiver disease	42
3)	Child-Turcotte-Pugh Scoring System for Cirrhosis	49
4)	Summary of postoperative clinical results in cirrhotic patients	61
5)	NYHA classification	74
6)	Demographic data for both groups under study	82
7)	Sex distribution among both groups under study	83
8)	Cardiac diagnosis, NYHA Class and History of MI among groups under study	85
9)	EDD, ESD and RVD among groups under study.	86
10)	FS and EF among groups under study	86
11)	EURO score of the patients under study.	88
12)	Hepatic Diagnosis, Hepatitis virus, Bilharziasis and Ascites among groups under study.	90
13)	CH-P scores among groups under study	92
14)	DM, Hypertension and COPD among groups under study.	94
15)	Preoperative and postoperative neurological insult and renal failure among groups under study.	96
16)	Type of operations among groups under study.	97
17)	Use of CP bypass and systemic temperature among groups under study.	98
18)	Mean Aortic cross clamp times and bypass times among groups under study.	100
19)	Mean preoperative and postoperative HB among groups under study	102
20)	Mean preoperative and postoperative WBCs count among groups under study.	104
21)	Mean preoperative and postoperative Platelets count among groups under study.	106
22)	Mean preoperative and postoperative serum Urea among groups under study.	108

23)	Mean preoperative and postoperative serum Creatinine among groups under study.	110
24)	Mean preoperative and postoperative serum Bilirubin among groups under study.	112
25)	Mean preoperative and postoperative serum Albumin among groups under study	114
26)	Mean preoperative and postoperative serum ALT among groups under study.	116
27)	Mean preoperative and postoperative serum AST among groups under study.	118
28)	Mean preoperative and postoperative Prothrombin time among groups under study.	120
29)	Mean preoperative and postoperative INR among groups under study.	122
30)	Mean preoperative PTT among groups under study.	123
31)	Mean chest drain, Blood and plasma transfusion among groups under study.	126
32)	Arrhythmias, MI, low CO, pleural effusion, pericardial effusion, cardiac morbidity, Respiratory complications, infection, hematemesis and hepatic impairment among groups under study.	131
33)	Mortality and suspected cause of death among groups under study.	133
34)	Reopening, Morbidity and Mortality among groups under study.	134
35)	Comparison between the survivors and nonsurvivors in the Cirrhotic group (nonparametric data)	135
36)	Comparison between the survivors and nonsurvivors in the Cirrhotic group (parametric data).	136
37)	Correlation of Ch-P and EuroSCORE to postoperative outcome.	137
38)	Cutoff point of Ch-P score in relation to the Mortality.	138
39)	cutoff point of CH-P score in relation to the Morbidity	139
40)	Cutoff point of CH-P score in relation to the Cardiac Morbidity	140
41)	Cutoff point of Right Vent dimension in relation to the Cardiac Morbidity	141
42)	Correlations of systemic temperature to Morbidity and Mortality	142
43)	Summary of published studies and our study.	144
44)	Recommended cardiac surgical approaches in cirrhotic patients	162

LIST OF FIGURE

Fig No	Subject	Page
1.	Abdominal viscera as related to the subdivision of the abdominal cavity	3
2.	Posterior aspect of the liver, showing its peritoneal connections divided close to its surfaces	5
3.	The superior, anterior and right lateral surfaces of the liver	6
4.	Section through a hepatic lobule (human) (after Sobotta). Stained with haematoxylin and eosin. Magnification ×70	10
5.	Diagram of the histological organization of the liver	10
6.	Diagram of the concept of forced sieving	12
7.	Coagulation Cascade	20
8.	urea cycle	22
9.	Mean age and weight for both groups under study	82
10.	Sex distribution among both groups under study	83
11.	Cardiac diagnosis, NYHA Class and History of MI among groups under study	85
12.	EDD and ESD among groups under study	87
13.	FS and EF among groups under study	87
14.	EURO score of the patients under study	88
15.	Hepatic Diagnosis, Hepatitis virus, Bilharziasis and Ascites among groups under study	91
16.	CH-P scores among groups under study	92
17.	DM, Hypertension and COPD among groups under study	94
18.	Preoperative and postoperative neurological insult and renal failure among groups under study.	96
19.	Type of operations among groups under study.	97
20.	CP bypass and systemic temperature among groups under study	99
21.	Aortic cross clamp times and bypass times among groups under study	100
22.	Mean preoperative and postoperative HB among groups under study.	102
23.	Mean preoperative and postoperative WBCs count among groups under study.	104
24.	Mean preoperative and postoperative Platelets count among groups under study.	106
25.	Mean preoperative and postoperative serum Urea among groups under study.	108

26.	Mean preoperative and postoperative serum Creatinine among groups under study	110
27.	Mean preoperative and postoperative serum Bilirubin among groups under study.	112
28.	Mean preoperative and postoperative serum Albumin among groups under study.	114
29.	Mean preoperative and postoperative serum ALT among groups under study.	116
30.	Mean preoperative and postoperative serum AST among groups under study.	118
31.	Mean preoperative and postoperative Prothrombin time among groups under study	120
32.	Mean preoperative and postoperative INR among groups under study	122
33.	Mean preoperative PTT among groups under study.	123
34.	Mean chest drain, Blood and plasma transfusion among groups under study.	126
35.	Mean ventilation and ICU times among groups under study.	127
36.	Mean post ICU times among groups under study.	127
37.	Arrhythmias, MI, low CO, pleural effusion, pericardial effusion, cardiac morbidity, Respiratory complications, infection, hematemesis and hepatic impairment among groups under study.	132
38.	Reopening, Morbidity and Mortality among groups under study.	134
39.	ROC curve of Ch-P score in relation to the Mortality	138
40.	cutoff point of Ch-P score in relation to the Mortality	138
41.	ROC curve of CH-P score in relation to the Morbidity	139
42.	cutoff point of CH-P score in relation to the Morbidity	139
43.	ROC curve of CH-P score in relation to the Cardiac Morbidity	140
44.	Cutoff point of CH-P score in relation to the Cardiac Morbidity	140
45.	ROC curve of Right Vent dimension in relation to the Mortality.	141
46.	Cutoff point of Right Vent dimension in relation to the Mortality.	141
47.	Algorithm for the management of patients with suspected liver cirrhosis	162

INTRODUCTION

Over time, the spectrum of surgical procedures available to patients with cardiac and great vessels disease continues to diversify and to mature. In parallel, our ability to match a widening range of surgical procedures with the individual needs of the patient has evolved as well. The relationships among preoperative patient-related risk factors and procedure-related perioperative care form the basis of the ongoing process of surgical care [1].

As techniques of operation and postoperative patient care improve, with resulting satisfactory clinical outcome, the number of patients with preoperative comorbidities who undergo major surgery is increasing. Currently, however, clinical outcomes after major surgery in patients with more advanced liver dysfunction, i.e., cirrhosis, are still unsatisfactory [2].

Schistosomal liver disease (SLD) in Egypt is significantly associated with HCV infection, with the predominance of genotype 4. Concurrent HCV infection and SLD result in much more severe liver disease than that seen with either disease alone. However, the activity of HCV infection seems to be partially suppressed in patients with SLD [3].

Congestive heart failure owing to myocardial infarction, cardiomyopathy, rheumatic heart disease, or constrictive pericarditis increases hepatic venous pressure and decreases hepatic blood flow, with resulting congestive liver fibrosis and cirrhosis. Multiple medications for cardiac disorders and blood transfusion during prior cardiac surgery may also compromise liver function. Accordingly, a close association between cardiac and liver disorders exists, and we occasionally encounter patients with the pathognomonic features. Despite the circumstances, patients with cirrhosis are less frequently referred for elective open heart surgery because of their considerably compromised health status and decreased life expectancy [2].

Because the number of patients reported about this issue is small, and morbidity and mortality rates after cardiac surgery using CPB in patients with this comorbidity are considerably high, definitive recommendations and indications for operation have not been conclusively shown. Recent studies demonstrated that although the incidence of postoperative complications was high, patients with mild cirrhosis tolerated open heart surgery well [4, 5].


The aim of the work

This prospective, case-controlled clinical study was designed to increase the chance of patients with liver cirrhosis who had a correctable cardiac lesion for a good outcome and good quality of life.

REVIEW OF LITERATURE ANATOMICAL CONSIDERATION

Gross and Surface Anatomy of the Liver

The liver lies in the right upper quadrant of the abdominal cavity. Beneath and attached to the diaphragm. It is the largest gland in the human body, weighing approximately 1500g in the adult. The relatively large size of the liver (especially the left lobe) at birth accounts for, in part, the bulging prominence of the infant's abdomen. In the adult, the normal liver extends from approximately the right fifth intercostal space along the midclavicular line down to or slightly below the costal margin, thus lying essentially under the protection of the rib cage (Fig. 1).



(Fig.1): Abdominal viscera as related to the subdivision of the abdominal cavity [6].

The anterior border of the liver lies on the transpyloric plane, about a hand's breadth below the xiphisternal joint. The gallbladder is usually found on the transpyloric plane along the midclavicular line [6].

On a visual basis, the liver is divided into a left half and a right half by the peritoneal fold (falciform ligament) which connects the liver to the diaphragm and the anterior abdominal wall. Functionally, however, the division of the liver is not based on the falciform ligament but rather on a plane that passes through the gallbladder and inferior vena cava [7].

• Lobes:

The liver is divided into four lobes. They are supplied by right and left branches of the portal veins and hepatic artery proper, and their bile drains into the right and left hepatic ducts. As noted above, the left and right lobes are divided anatomically at the line of attachment of the falciform ligament. The right lobe, however, is further subdivided on its inferior-posterior surfaces into two smaller lobes; the quadrate and caudate lobes. The quadrate lobe is on the inferior surface, rectangular, bounded on the left by the fissure for the ligamentum teres, posteriorly by the porta hepatis, and on the right by the fossa of the gallbladder. The caudate lobe is situated on the posterior liver surface, bounded on the left by the fissure for the ligamentum venosum and on the right by the groove for the inferior vena cava .Occasionally, the lower border of the right hepatic lobe may project downward for a considerable distance as a broad tongue-like process (Riedel's lobe) [7].

• <u>Ligaments</u>:

As the falciform ligament reaches the liver, its two layers separate, exposing an area on the superior surface of the liver that is devoid of peritoneum. The left layer of the falciform ligament then becomes continuous with the anterior layer of the left triangular ligament, and the right layer becomes continuous with the upper layer of the coronary ligament. The coronary ligament is formed by a reflection of the peritoneum from the diaphragm to the superior and posterior surfaces in the right lobe. (Fig. 2) It consists of an upper layer and a lower layer continuous at the right extremities with the right triangular ligament of